최고 Dkb 팟캐스트 (2024)

1
Clinical Management Considerations in Mild Asthma 23:47

1M ago23:47

23:47

Mild asthma. For patients showing wheezing and shortness of breath on moderate exertion, it’s one of the most common diagnoses, even when breath sounds are clear and pulmonary function testing is normal. What makes mild asthma “mild”? The key guidelines base the stage of a patient’s asthma on how difficult it is to treat. Does that mean the frequen…

1
PH in the Clinic: The Revised WHO Classifications 25:30

3M ago25:30

25:30

Pulmonary hypertension. The 2022 ESC/ERS revised guidelines have redefined it. New evidence from ongoing and completed clinical trials have led to updates in diagnostic thresholds and treatment algorithms. New agents — some approved, others advancing through the pipeline — promise improved efficacy and safety for a variety of patients. What does it…

1
Clinical Approaches to Marginalized Populations 35:03

3M ago35:03

35:03

In part 1 of this eHIV Review Special Edition (still available at eHIVreview.org), eHIV Review Program Director Justin Alves, Nurse Educator at Boston Medical Center, reviewed the recent evidence describing some of the barriers to care experienced by marginalized individuals at risk for or living with HIV. In this Part 2 issue, he again calls upon …

1
Addressing the Needs of Marginalized Populations - Mehtani 4:43

3M ago4:43

4:43

Marginalized individuals at risk for or living with HIV — the formerly incarcerated, immigrants, people with unstable housing, residents of rural communities, the rising number with substance use disorder — have long faced disparities in obtaining adequate health care. What do HCPs need to know to understand the unique needs of these underserved po…

1
Addressing the Needs of Marginalized Populations - Loukas 2:18

3M ago2:18

2:18

Marginalized individuals at risk for or living with HIV — the formerly incarcerated, immigrants, people with unstable housing, residents of rural communities, the rising number with substance use disorder — have long faced disparities in obtaining adequate health care. What do HCPs need to know to understand the unique needs of these underserved po…

1
HIV Stigma: A Psychologist’s Viewpoint 30:59

4M ago30:59

30:59

A wealth of evidence confirms that adolescents and young adults (AYA) are indeed a priority population whose needs must be addressed for the US Ending the HIV Epidemic program to be successful. What do providers need to know about AYA to bring more of these patients into the HIV care continuum? What should they be doing? And what should they avoid …

1
Using the New Biomarkers in Clinical Practice 25:55

5M ago25:55

25:55

NfL — neurofilament light, from the blood, not the CSF. Is it a reliable indicator of MS activity, a predictor of relapse-related disability, and a monitor of treatment efficacy? OCT — optical coherence tomography. Fast, safe, reliable, and repeatable, it can reveal the cellular layers inside the retina. But how well does what OCT shows correlate w…

1
AYA and Ending the HIV Epidemic 25:29

5M ago25:29

25:29

A wealth of evidence confirms that adolescents and young adults (AYA) are indeed a priority population whose needs must be addressed for the US Ending the HIV Epidemic program to be successful. What do providers need to know about AYA to bring more of these patients into the HIV care continuum? What should they be doing? And what should they avoid …

1
Emerging MS Clinical Options 24:18

5M ago24:18

24:18

Has the place for BTK inhibitors in MS been determined? How well do extended interval or alternative B cell depletion dosing regimens work, and for which patients? Do the data support HSCT (hematopoietic stem cell transplant) over high-efficacy DMT — again, for which patients, and with what efficacy and safety? Join us, as guest host Dr. Cole Harri…

1
#19 Die finale Folge mit den Gewinner*innen des VR-Kunstpreises 47:12

6M ago47:12

47:12

Es ist offiziell! Die Gewinner*innen des VR-Kunstpreises der DKB in Kooperation mit CAA Berlin stehen fest. Trommelwirbel für Platz 1: Dieser geht an Mohsen Hazrati für „Fãl Project [none-AI]“. Rebecca Merlic belegt mit ihrer Arbeit „Glitchbodies“ den 2. Platz, und Platz 3 geht an Anan Fries für ihre Arbeit „Posthuman Wombs“. In dieser Folge werden…

1
Clinical and Radiologic Features of an MS Prodrome 27:11

8M ago27:11

27:11

What’s the evidence supporting the existence of an MS prodromal phase — where the biology of the disease has begun but the symptoms typical of MS have not yet appeared? Are there biomarkers to help identify it? Imaging abnormalities? And how can diagnosing a prodrome benefit patients? Join us as we discuss these questions with Dr. Naila Makhani fro…

1
#18 Die VR-Kunst-Ausstellung Unleashed Utopias 29:00

8M ago29:00

29:00

Wie wäre es, wenn alle Menschen unabhängig von ihrem Geschlecht Kinder bekommen könnten? Wie verwandelt künstliche Intelligenz das Innenleben eines Menschen in Kunst? Kann KI uns die Zukunft voraussagen? Diese und weitere spannende Fragen finden ihre Antworten auf künstlerische Art und Weise in der Ausstellung „Unleashed Utopias“. Kuratorin dieser …

1
#17 Was erwartet uns beim Digital Art Lab im Rahmen der Berlin Art Week 2023? 29:52

8M ago29:52

29:52

Wir müssen mehr reden – und zwar über VR-Kunst! Warum? Expert*innen sind sich einig: Wir wissen zu wenig darüber, auch in der Kunst-Szene und dass, obwohl VR-Kunst jetzt und in der Zukunft eine große Rolle spielen wird. Aus diesem Grund feiert das Digital Art Lab Premiere, ein Treffpunkt für digitale Kunst begleitend zur Berlin Art Week vom 13. bis…

1
Mitigating MS DMT Infection Risk 21:19

9M ago21:19

21:19

Clinicians prescribing the increasingly higher efficacy B-cell depletion or S1P modulators therapies — how aware are they of the newer concerns about safety? Which of their patients may be in greater danger of acquiring PML and/or opportunistic infections? The vaccinations commonly recommended for the general population (eg, COVID-19) — do individu…

1
Delivering High-Quality HIV Care to Cisgender and Transgender Women 26:14

9M ago26:14

26:14

Why do cisgender and transgender women, and particularly women of color, account for such a disproportionate percentage of HIV infections in the US? Why are so many so reluctant to accept PrEP? What can clinicians do to bridge this critical gap in essential HIV services? These are some of the questions Guest Author Dr. Kathleen McManus, from the Di…

1
Overcoming Barriers to MS Care 23:08

9M ago23:08

23:08

Too many individuals with MS are not receiving access to the most effective care. Why? What’s behind these disparities? And what can individual clinicians do to help remove the barriers that prevent equitable care for all patients?Join us, as Dr. Dorlan Kimbrough, from the division of Neurology, Multiple Sclerosis, and Neuroimmunology at the Duke U…

1
Newer NNRTI Agents in Clinical Practice 27:40

10M ago27:40

27:40

Non-nucleoside reverse transcriptase inhibitors (NNRTIs). Rilpivirine, in combination with cabotegravir, provides a long-acting injectable option for both treatment and PrEP. But what risk factors have been associated with virologic failure? Doravirine appears to provide a favorable impact on weight and lipid outcomes, but with a lower genetic barr…

1
#16 Immersive Erlebnisse mit Kunst 29:43

10M ago29:43

29:43

Wenn Monets Seerosen plötzlich durch die Luft schweben oder der Schrei von Edvard Munch sich greifbar im Raum ausbreitet, dann sind digitale Anwendungen im Spiel. In dieser Folge von „Virtuell Virtuos“ geht es um so genannte immersive Erlebnisse von bestehenden Kunstwerken. Die Journalistin Tanja Lepczynski und Tina Sauerländer, Expertin für VR-Kun…

1
#15 Expanded Realities: Wie steht es um VR in der Lehre? 36:31

11M ago36:31

36:31

In dieser Folge geht es um die Frage, wie es im Zeitalter der Digitalisierung mit VR-Kunst in der Lehre aussieht? Wie groß ist der Anteil an VR in Unis und Hochschulen? Die Journalistin Tanja Lepczynski und Kuratorin Tina Sauerländer sprechen dazu mit einem Hochschulprofessor. Philip Hausmeier lehrt an der Hochschule Darmstadt VR. Dafür hat er geme…

1
Clinical Opinions: Managing Spasticity in Individuals with MS 41:50

11M ago41:50

41:50

How burdensome is spasticity for patients with MS? What’s the approach to treatment, and how effective is it? What do patients and clinicians need to know about cannabis-based therapies? These are the key questions Program Director Dr. Michael Kornberg from the Johns Hopkins School of Medicine discusses with guest MS spasticity experts in this seco…

1
Emerging HIV Therapies and Potential Clinical Uses 25:37

12M ago25:37

25:37

Hosted on Acast. See acast.com/privacy for more information.

1
#14 VR KUNSTPREIS #2: Virtuelle Utopien 33:33

1y ago33:33

33:33

Wie sieht die Welt in Zukunft aus? Mit dieser Frage beschäftigt sich nicht nur die Forschung, sondern auch die Kunst. Die fünf Stipendiatinnen des VR-Kunstpreises der DKB in Kooperation mit CAA Berlin haben virtuelle Utopien entworfen. Ihre Werke werden ab 8. September 2023 in Berlin im Haus am Lützowplatz zu sehen sein. Tina Sauerländer ist auch i…

1
#13 Trailer zur 2. Staffel Virtuell Virtuos 2:50

1y ago2:50

2:50

Der VR KUNSTPREIS der DKB in Kooperation mit CAA Berlin geht in die 2. Runde: Am 8. September 2023 wird die große VR KUNSTPREIS Ausstellung im Haus am Lützowplatz eröffnet. In der 2. Staffel unseres Podcasts "Virtuell Virtuos" sprechen wir daher über aktuelle Trends in der Virtual Reality Kunst sowie über die Stipendiat*innen des VR KUNSTPREIS, ihr…

1
Hepatitis B: Our Current Understanding 41:45

1y ago41:45

41:45

Hepatitis B. It may not be curable yet, but as our knowledge continues to grow, so does our ability to benefit our patients today as we prepare them for tomorrow. That’s the focus of this Special HBV Edition of eViralHepatitis Review. The first part of this program presented an evidence-based expert commentary by eViralHepatitis Review Program Dire…

1
MS Risk Factors and Outcomes 17:34

1y ago17:34

17:34

In her Expert Commentary, Dr. Melanie Ward from West Virginia University’s Rockefeller Neuroscience Institute provided analysis of the newer data describing the modifiable and nonmodifiable risk factors for developing MS and/or increasing the rate of disease progression and disability. Join us for this podcast as Dr. Ward explains how these finding…

1
1/26/2023 - COVID-19 Subvariants XBB and XBB.1.5 15:27

1y ago15:27

15:27

Dr. Paul Auwaerter discusses XBB and XBB.1.5 subvariants and the respiratory virus season. Topics: *Why XBB and XBB.1.5 subvariants are more transmissible than other subvariants, but less virulent *Effect of Paxlovid on hospitalization and mortality *Summary of the flu and RSV season *Deciding when to treat a COVID-19 patient Post-test for CME/CE c…

1
Stigma and HIV Care in LGBTQ+ Persons 20:30

1+ y ago20:30

20:30

Stigma. What is it, and where does it come from? How do LGBTQ+ individuals, particularly those with HIV, experience it? How does stigma affect their mental health? What effect does it have on their engagement in HIV care? What do health care providers need to change to minimize stigma in their practices? These are some of the questions advanced pra…

1
CF and Diet and Nutrition: The Changing Paradigm 38:22

1+ y ago38:22

38:22

Individuals with cystic fibrosis — adults as well infants and children — have long struggled to gain and maintain their weight. But how has the current widespread use of highly effective modulator treatments — HEMT — changed that situation? That’s the focus of this eCysticFibrosis Review Special Edition: CF and Nutrition and HEMT.  The first part o…

1
Newer Options for Treatment-Experienced Patients Podcast 33:52

1+ y ago33:52

33:52

Treatment-experienced patients with RAMs — resistance-associated mutations — remain a difficult management challenge. Every case of HIV drug resistance requires a therapeutic regimen individualized for each patient’s ART history. How will new and in-development agents affect the equation? Which drug combinations are right? Where does the balance be…

1
Effects of Race/Ethnicity on MS Diagnosis and Treatment 20:52

1+ y ago20:52

20:52

How aware are clinicians that MS should no longer be considered a “White people only” disease? What roles have race and ethnicity been shown to play in MS disease severity and disability progression? What do health care professionals need to know to provide the most effective care for all their patients? Join Dr. Yujie Wang from the University of W…

1
ETI (CFTR Triple Therapy): Clinical Opportunities 28:08

1+ y ago28:08

28:08

The advent of triple CFTR modulator therapy – ETI (elexacaftor/tezacaftor/ivacaftor) — poses a number of clinical questions. Are three agents really better than two? For which patients, in what circumstances? What does the CF Team need to understand to ensure their patients get maximum benefit? Join us as we explore these questions with guest autho…

1
Weight Gain in PLWH: A Clinical Concern 27:22

1+ y ago27:22

27:22

Most people living with HIV gain weight when initiating ART. For some, the weight gain signifies a “return to health”; for others, the additional weight can be clinically significant and may be strongly associated with an increased risk of metabolic abnormalities. What causes this weight gain? How can patients most at risk for weight-related comorb…

1
Clinical Considerations for In-Development MS Treatments 24:40

1+ y ago24:40

24:40

Where’s the newer MS research leading? How has our understanding of noninflammatory progressive MS changed? How might these findings affect what happens in the clinic? Join us as we discuss these and other questions with Dr. Michael Kornberg from the Johns Hopkins School of Medicine in this eMultipleSclerosis Review podcast. Take our post-test to c…

1
8/10/2022 - COVID-19 Testing Interview Part 2 19:48

1+ y ago19:48

19:48

Dr. Paul Auwaerter interviews Dr. Michael Mina about COVID-19 testing. Topics: *Why are we seeing prolonged antigen positive test results? *Do we know when someone is infectious? For how long? *Speculating on the cause of Paxlovid rebound Post-test for CME/CE credit: https://covid19.dkbmed.com/multispecialty/7-28-22-episode/eval Access our resource…

1
7/28/2022 - COVID-19 Immunity Interview Part 1 24:20

1+ y ago24:20

24:20

Dr. Paul Auwaerter interviews Dr. Michael Mina about COVID-19 immunity. Topics: *Is COVID-19 here to stay? *Immunity evasiveness of Omicron BA.4 and BA.5 *Expectations for the fall and winter 2022 *Thoughts on upcoming booster reformulation *Should you get a booster now or wait? Post-test for CME/CE credit: https://covid19.dkbmed.com/multispecialty…

1
Is that MS Diagnosis Accurate? 25:39

2y ago25:39

25:39

Is it true that a significant number of patients being treated for MS may not actually have the disease? What are the red flags — warnings that something about the patient’s condition does not meet the accepted MS diagnostic criteria — that need to be investigated? Join us in this eMultipleSclerosis Review podcast, as Neuroimmunologist Dr. Gabriell…

1
Nonpharmacologic Symptom Management 25:56

2y ago25:56

25:56

In this Issue: Fatigue. Urinary dysfunction. Constipation. Spasticity and gait problems. Providing relief from these common MS symptoms often requires clinicians to go beyond the prescription pad to recommend nonpharmacologic treatments. What works? What doesn’t? What does the evidence say? Join us as Dr. W. Oliver Tobin from the Mayo Clinic discus…

1
COVID-19: The Morbidity/Mortality Risk 22:51

2y ago22:51

22:51

Are PLWH at higher risk for increased mortality from COVID-19 infection? How important is it for PWLH to get vaccinated and boosted? Is breakthrough COVID-19 infection more likely to occur among PLWH? What about “long COVID” (PASC)? Join Clinical Research Nurse Diane Kanjilal, manager of the Infectious Disease Clinical Research Unit at Massachusett…

1
COVID-19: Then and Now 25:36

2y ago25:36

25:36

What was it like for a frontline critical care pulmonologist at the very beginning of the COVID-19 epidemic? On the frontlines as the epidemic became pandemic? What’s it like today, with new variants and new in-patient and out-patient treatments? What are the key differences between then and now, what have we learned, and how can we be better prepa…

1
Pulmonary Exacerbations and IV Antibiotics 18:43

2y ago18:43

18:43

Managing pulmonary exacerbations in people with cystic fibrosis: is there high-grade evidence to support best practices? How helpful is the most current guidance? Does the recent research challenge the current standard of care? Join us for this eCysticFibrosis Review podcast, as Dr. D.B. Sanders from the Indiana University School of Medicine explai…

1
7/6/2022 - COVID-19 Vaccine Boosters 17:55

2y ago17:55

17:55

Dr. Paul Auwaerter discusses COVID-19 vaccine boosters. Topics: *Should your patients get the booster now or wait? *FDA advisory committee votes to include Omicron component in COVID-19 booster vaccines *COVID-19 case and mortality projections for this winter *Booster timing for children and adults Post-test for CME/CE credit: https://covid19.dkbme…

1
Race, Ethnicity, and Cystic Fibrosis 22:59

2y ago22:59

22:59

Race and ethnicity. How do they affect a patient’s ability to receive a timely and accurate cystic fibrosis diagnosis? How do the social determinants of health limit access to appropriate CF treatment and produce poorer outcomes? That’s what we’re here to talk about today with Dr. Jennifer Taylor-Cousar from National Jewish Health and Children’s Ho…

1
6/1/2022 - State of COVID-19 19:20

2y ago19:20

19:20

Dr. Paul Auwaerter discusses the current state of COVID-19 including treatment updates. Topics: *Information on new Omicron subvariants *CDC advisory about rebound COVID-19 *Latest treatment information *Post-COVID conditions Post-test for CME/CE credit: https://covid19.dkbmed.com/multispecialty/6-1-22-episode/eval Access our resource center, downl…

1
5/11/2022 - COVID-19 Omicron Impact on Vaccines 17:18

2y ago17:18

17:18

Dr. Paul Auwaerter discusses the effect of the Omicron variant, including its subvariants, on COVID-19 vaccines. Topics: *Impact of Omicron on mRNA boosters *Analyzing Omicron and BA.2 subvariants *Interpreting CDC vaccine data *Protection level of one-way masking Post-test for CME/CE credit: https://covid19.dkbmed.com/multispecialty/5-11-22-episod…

1
4/26/2022 - COVID-19 Prevention Update 49:59

2y ago49:59

49:59

Paul G. Auwaerter, MD, MBA, FIDSA and Michael Angarone, DO, FIDSA discuss the latest guidelines for prevention of COVID-19. Topics: *Updates on the BA.2 subvariant *Who should get a second booster? And when? *What conditions and factors place people at higher risk for severe COVID? *Pre-exposure prophylaxis for COVID-19 prevention *Mitigating risk …

1
4/6/2022 - New COVID-19 Treatment Guidelines 43:41

2y ago43:41

43:41

Paul G. Auwaerter, MD, MBA, FIDSA and David Klimpl, MD discuss current treatments for patients hospitalized with COVID-19. Topics: *New data on efficacy of available therapies *Immunomodulators for critical care patients *Updated NIH recommendations Post-test for CME/CE credit: https://covid19.dkbmed.com/multispecialty/4-6-22-episode/eval Access ou…

1
Clinical Uses of LA Injectable ART 25:51

2y ago25:51

25:51

Long-acting injectable antiretroviral therapy is expected to improve adherence, reduce patient burden, and lower community viral load. But for which patients is it suitable? Can it be used as pre-exposure prophylaxis? How does the promise of long-acting ART actually mean in practice?Join us for this eHIV Review podcast, as Dr. Tanya…

1
4/13/2022 - COVID-19 Vaccine Boosters & BA.2 21:09

2y ago21:09

21:09

Dr. Paul Auwaerter discusses new vaccine boosters, global impact of the pandemic, and the BA.2 Subvariant. Topics: *New boosters in the future? *Challenges of additional boosters *Cardiac concerns with COVID-19 vaccines? *Collateral effects from the pandemic *Latest news on BA.2 Subvariant Post-test for CME/CE credit: https://covid19.dkbmed.com/mul…

1
3/30/2022 - COVID-19 BA.2 Subvariant & Boosters 18:00

2y ago18:00

18:00

Dr. Paul Auwaerter discusses the BA.2 Subvariant and the recent authorization from the FDA for second booster dose. Topics: *Virulence of BA.2 vs Omicron and Delta * Therapeutic activity of monoclonal antibodies against BA.2 *Details of approval for booster #2 (4th and 5th dose) *Are there advantages to mixing mRNA vaccines? Post-test for CME/CE cr…

1
3/24/2022 - COVID-19 Lessons Learned 16:04

2y ago16:04

16:04

Dr. Paul Auwaerter discusses what we learned from the COVID-19 pandemic. Topics: *Reviewing the timeline of events and variants *What happens next? *Preparing for the future *The new role of monoclonal antibodies Post-test for CME/CE credit: https://covid19.dkbmed.com/multispecialty/3-24-22-episode/eval Access our resource center, download webinar …

들어볼 가치가 있는 팟캐스트

Dkb 팟 캐스트

들어볼 가치가 있는 팟캐스트

빠른 참조 가이드